{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-130372","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.678181+00:00","generated_at":"2026-05-15T08:27:14.745855+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neumora FY2025 net loss $236.9M; NMRA-511 positive data; NMRA-215 delayed to Q1 2027; cash to Q3 2027","bullets":["Cash $182.5M; FY net loss $236.9M; R&D $176.1M, G&A $60.1M; cash runway into Q3 2027.","NMRA-511: pre-specified analysis (NPI-AA≥4) shows Cohen's d 0.34 on CMAI total, 0.51 on CMAI aggression.","Navacaprant: KOASTAL-2 and -3 fully enrolled (>400 each); topline readout expected Q2 2026.","M4 franchise: NMRA-898 lead; Phase 1 shows ~80-100h half-life, target engagement; MAD study data H2 2026.","NMRA-215: 12-week DIO data supports switch/maintenance; tox finding in 5/142 rats; clinical now Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-130372","json":"https://secwatch.observer/filing/0001193125-26-130372.json","markdown":"https://secwatch.observer/filing/0001193125-26-130372.md","text":"https://secwatch.observer/filing/0001193125-26-130372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526130372/0001193125-26-130372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526130372/nmra-20260330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:27:14.745855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9463cc4819a12041dbc470d8d38bb9791d495094","claim":"Neumora Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"On March 30, 2026, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526130372/0001193125-26-130372-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}